

Dermira, Inc.
Form 8-K
March 05, 2018
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 5, 2018

Dermira, Inc.

(Exact Name of the Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-36668
(Commission File Number)

27-3267680
(IRS Employer Identification No.)

275 Middlefield Road, Suite 150

Menlo Park, California 94025
(Address of Principal Executive Offices) (Zip Code)
(650) 421-7200

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, If Changed Since Last Report)

Edgar Filing: Dermira, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement
communications
pursuant to Rule
13e-4(c) under the
Exchange Act (17
CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item Other Events.

8.01

On March 5, 2018, Dermira, Inc. issued a press release announcing the results of its two Phase 3 trials evaluating olumacostat glasaretil in patients with acne vulgaris. The press release is being filed as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
-------------	-------------

99.1	<u>Press release of Dermira, Inc., dated March 5, 2018.</u>
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dermira, Inc.

Date: March 5, 2018 /s/ Andrew L. Guggenhime
Andrew L. Guggenhime

Chief Operating Officer and Chief Financial Officer